Email Updates

Search form

You are here

26 JULY 2019 VOLUME 20 ISSUE 28

Media Coverage

  • Final results of HOPE (HIV Open-label Prevention Extension [MTN-025]), a phase 3 open-label extension trial, show high uptake and lower-than-anticipated HIV-1 incidence among women in southern and eastern Africa who used the ring continuously for 4 weeks and then swapped it out for a new one. The findings were presented at the 10th IAS Conference on HIV Science (IAS 2019).

    July 26, 2019
    Contagion Live
  • TB and HIV both are preventable, but cutting the chain of transmission of HIV and TB is proving to be a daunting task. Treatment exists for both TB and HIV but disease-burden and deaths every year are indeed alarming. With countdown on towards TB and AIDS elimination targets for 2030, the writing on the wall is clear: business as usual and 'more of the same' approach is more likely to fail us.

    July 26, 2019
    Modern Ghana
  • ECHO, the landmark trial demonstrating that injectable hormonal contraceptives do not raise women’s risk of acquiring HIV, released its results just a month before this week’s 10th International AIDS Society Conference on HIV Science (IAS 2019). While providing reassuring news about contraception, the study also revealed an unacceptably high incidence of HIV among trial participants, despite the prevention services that had been provided.

    July 26, 2019
    aidsmap
  • Among men who are at high risk for HIV infection, only about one in three is taking a drug to prevent transmission of the virus, according to a survey from the Centers for Disease Control and Prevention. The drug, Truvada, is taken daily as part of a preventive strategy called pre-exposure prophylaxis, or PrEP.

    July 25, 2019
    New York Times
  • The 2019 HIV and Hepatitis B Cure Forum took place on 20-21st July immediately before the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City this week. This year, it included research into curing chronic hepatitis B infection as well as HIV, as the two viruses share similarities, the chief one being that they mainly cause disease by generating a damaging immune response to their viruses rather than, as other viruses do, killing cells directly.

    July 24, 2019
    aidsmap
  • A whip-thin length of polymer loaded with islatravir, Merck's investigational HIV prevention drug, and implanted into the arm is being investigated as a future option for people who have a hard time taking pills.

    July 24, 2019
    Medscape
  • Health officials and AIDS advocates in San Francisco hope to expand the use of an effective HIV prevention drug with a new approach that requires fewer pills than the standard once-a-day regimen.

    July 24, 2019
    San Francisco Chronicle
  • A "mosaic" vaccine against HIV was well-tolerated and able to produce an immune response against multiple clades, or disease subtypes, in healthy volunteers, a researcher said here.

    July 24, 2019
    MedPage Today
  • People not infected with HIV can take a daily pill to prevent themselves from contracting the virus, a proven strategy called pre-exposure prophylaxis (PrEP). But many people who start PrEP do not stick with it or take the pills only intermittently, undermining its effectiveness. This week, at the International AIDS Conference in Mexico City, the pharmaceutical giant Merck & Co. reported a potential solution: a slow-release implant of an experimental antiretroviral (ARV) drug designed to be long-lasting in the body.

    July 24, 2019
    Science
  • A new study reports successful immunization against a so-far invincible “death star” strain of an HIV-related laboratory virus (SIVmac239) and another tough strain. The new approach also achieves long-term protection with a single dose, showing that gene therapy could allow broad and durable protection, based on a modified form of the CD4 protein that allows HIV entry into human cells.

    July 24, 2019
    News Medical
  • The World Health Organization (WHO) has updated its recommendation for pre-exposure prophylaxis (PrEP) to include event-driven PrEP taken before and after sex – also called on-demand PrEP or the 2+1+1 schedule – as an HIV prevention option for men who have sex with men.

    July 24, 2019
    aidsmap
  • Kenya plans to enhance domestic funding to eradicate HIV/Aids that affects an estimated 5.1 percent of the population, an official said Tuesday. Regina Ombam, deputy director, HIV investments, National AIDS Control Council (NACC) told a health forum in Nairobi that currently foreign donors account for 70 percent of funding to combat the virus.

    July 23, 2019
    General
    Xinhua
  • In what could eventually become a milestone for HIV prevention, very preliminary tests of an implant containing a new drug suggest that it may protect against infection for a full year. The new implant, by the drug company Merck, was tested in just a dozen subjects for 12 weeks. But experts were quite excited at its potential to revolutionize the long battle against HIV

    July 23, 2019
    New York Times
  • First in-human data found that an implant for pre-exposure prophylaxis (PrEP) for HIV prevention was safe and long-acting, according to a small phase I trial presented here.

    July 23, 2019
    MedPage Today
  • After much hand-wringing, the World Health Organization (WHO) has issued new, reassuring guidance that dolutegravir (Tivicay, DTG) is recommended as a first- and second-line antiretroviral treatment across all populations.

    July 23, 2019
    The BodyPro
  • The former CEO of Lloyd’s bank will head an independent commission to end HIV transmissions in England. UK HIV charities, Terrence Higgins Trust and NAT (National AIDS Trust) created the HIV Commission. The year-long independent commission has the backing of the UK government. It will publish its findings in spring next. The findings will come after hosting a series of community events, a public online consultation, and a national call for evidence from those directly impacted by HIV.

    July 22, 2019
    General
    Gay Star News
  • On an otherwise quiet residential block, with a school on one side and a church on the other, a nightclub once drew crowds from all along the East Coast for some of Washington, D.C.’s most raucous parties. The center of the city’s black gay nightlife, the ClubHouse, would have hundreds of patrons wrapped in a line around the block waiting to get in on a given night. But in the early 1980s, the nightclub’s manager began to notice that certain regulars had stopped showing up. Many of them, it turned out, were starting to get sick. Some started dying.

    July 22, 2019
    General
    The Atlantic
  • China will soon start clinical trials to test the Human Immuno Virus (HIV) vaccine with 160 human volunteers. With no known cure for HIV till date, the Chinese Center for Disease Control and Prevention (CCDCP), in Beijing, has been working on the HIV vaccine since the first trial in 2007, to protect people from the HIV virus. The vaccine is called DNA-rTV and, in this second phase of human trials, is currently known to work on replication of the DNA of HIV in order to trigger the immunisation.

    July 22, 2019
    VICE
  • The roll-out of pre-exposure prophylaxis (PrEP) provides an opportunity to bring down the incidence of sexually transmitted infections (STIs), provided that PrEP and STI programmes are better co-ordinated and integrated, representatives from the World Health Organization (WHO) said yesterday at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City.

    July 22, 2019
    aidsmap
  • In a major step forward for HIV vaccine research, the US research agency will partner with a pharmaceutical company on a large-scale, advanced-stage clinical study on an HIV vaccine. If the trial is successful, the vaccine may become the first ever to be approved for HIV prevention. But the rise of PrEP has created unexpected challenges to study enrollment.

    July 17, 2019
    The BodyPro

Published Research

Announcements